

Simon Finfer
V. Marco Ranieri
B. Taylor Thompson
Philip S. Barie
Jean-François Dhainaut
Ivor S. Douglas
Bengt Gårdlund
John C. Marshall
Andrew Rhodes

Erratum to: Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock

Published online: 25 November 2010
© Copyright jointly held by Springer and ESICM 2010

The online version of the original article can be found under doi: [10.1007/s00134-008-1266-6](https://doi.org/10.1007/s00134-008-1266-6).

S. Finfer (✉)
Critical Care and Trauma,
The George Institute for International Health,
University of Sydney, PO Box M201, Missenden Road,
Sydney, NSW 2050, Australia
e-mail: sfinfer@george.org.au
Tel.: +61-2-96570348
Fax: +61-2-96570301

V. M. Ranieri
Ospedale S. Giovanni Battista-Molinette,
Università di Torino, Torino, Italy

B. T. Thompson
Pulmonary and Critical Care Unit, Bullfinch Building,
Room 148, Massachusetts General Hospital, 55 Fruit Street,
Boston, MA 02114, USA

P. S. Barie
Department of Surgery, P713A, Weill Cornell Medical College,
525 East 68 St, New York, NY 10065, USA

J.-F. Dhainaut
Cochin Port Royal Hospital-Paris Descartes University,
Paris, France

I. S. Douglas
Denver Health and University of Colorado, Denver, USA

B. Gårdlund
Department of Infectious Diseases, Karolinska University Hospital,
14186 Stockholm, Sweden

J. C. Marshall
Departments of Surgery and Critical Care Medicine,
St Michael's Hospital, 4th Floor Bond Wing, Rm. 4-007,
30 Bond Street, Toronto, ON M5B 1W8, Canada

A. Rhodes
Department of Intensive Care Medicine and Anaesthesia,
St George's Hospital, London SW17 0QT, UK

Erratum to: Intensive Care Med (2008) 34:1935–1947 DOI 10.1007/s00134-008-1266-6

Due to an oversight by the authors, incorrect data appeared in Table 2. The table is reproduced here with the corrected item in bold type.

Table 2 Serious bleeding rates in clinical trials of drotrecogin alfa (activated)

Study	Placebo <i>n</i> (%)	DAA <i>n</i> (%)	<i>P</i>
PROWESS	17 (2.0)	30 (3.5)	0.06
PROWESS (CNS)	1 (0.1)	2 (0.2)	NS
ADDRESS	28 (2.2)	51 (3.9)	0.01
ADDRESS (Day 0–6)	15 (1.2)	31 (2.4)	0.02
ADDRESS (CNS)	5 (0.4)	6 (0.5)	0.72
RESOLVE	16 (6.8)	16 (6.7)	0.97
RESOLVE (Day 0–6)	8 (3.4)	9 (3.8)	0.83
RESOLVE (CNS)	5 (2.1)	11 (4.6)	0.13
ENHANCE	–	155 (6.5)	–

Day 0–6: any serious bleeding event occurring during the DAA infusion period

CNS central nervous system bleeding